» Articles » PMID: 18326793

Pericardial Delivery of Omega-3 Fatty Acid: a Novel Approach to Reducing Myocardial Infarct Sizes and Arrhythmias

Overview
Date 2008 Mar 11
PMID 18326793
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Basic and clinical evidence suggests that omega-3 (n-3) polyunsaturated fatty acids (PUFAs) decrease fatal arrhythmias and infarct sizes. This study investigated if pericardial delivery of n-3 PUFAs would protect the myocardium from ischemic damages and arrhythmias. Acute myocardial infarctions were induced in 23 pigs with either 45 min balloon inflations or clamp occlusions of the left anterior descending coronary arteries and 180 min reperfusion. Docosahexaenoic acid (C22:6n-3, DHA, 45 mg), one of the main n-3 PUFAs in fish oil, was infused within the pericardial space only during the 40-min stabilizing phase, 45 min ischemia and initial 5 min reperfusion. Hemodynamics and cardiac functions were very similar between the DHA-treated and control groups. However, DHA therapy significantly reduced infarct sizes from 56.8 +/- 4.9% for controls (n = 12) to 28.8 +/- 7.9% (P < 0.01) for DHA-treated animals (n = 11). Compared with controls, DHA-treated animals significantly decreased heart rates and reduced ventricular arrhythmia scores during ischemia. Furthermore, three (25%) control animals experienced eight episodes of ventricular fibrillation (VF), and two died subsequent to unsuccessful defibrillation. In contrast, only 1 (9%) of 11 DHA-treated pigs elicited one episode of VF that was successfully converted via defibrillation to normal rhythm; thus, mortality was reduced from 17% in the controls to 0% in the DHA-treated animals. These data demonstrate that pericardial infusion of n-3 PUFA DHA can significantly reduce both malignant arrhythmias and infarct sizes in a porcine infarct model. Pericardial administration of n-3 PUFAs could represent a novel approach to treating or preventing myocardial infarctions.

Citing Articles

Marine Compounds and Age-Related Diseases: The Path from Pre-Clinical Research to Approved Drugs for the Treatment of Cardiovascular Diseases and Diabetes.

Giuliani M, Bigossi G, Lai G, Marcozzi S, Brunetti D, Malavolta M Mar Drugs. 2024; 22(5).

PMID: 38786601 PMC: 11123485. DOI: 10.3390/md22050210.


Micronized Acellular Matrix Biomaterial Leverages Eosinophils for Postinfarct Cardiac Repair.

Vasanthan V, Hassanabad A, Belke D, Teng G, Isidoro C, Dutta D JACC Basic Transl Sci. 2023; 8(8):939-954.

PMID: 37719429 PMC: 10504403. DOI: 10.1016/j.jacbts.2023.01.012.


Marine-Derived Compounds Applied in Cardiovascular Diseases: Submerged Medicinal Industry.

Akram W, Rihan M, Ahmed S, Arora S, Ahmad S, Vashishth R Mar Drugs. 2023; 21(3).

PMID: 36976242 PMC: 10052127. DOI: 10.3390/md21030193.


The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction.

Crisostomo V, Baez-Diaz C, Blanco-Blazquez V, Alvarez V, Lopez-Nieto E, Maestre J Sci Rep. 2021; 11(1):22155.

PMID: 34772964 PMC: 8590017. DOI: 10.1038/s41598-021-01728-y.


Microbiota, a New Playground for the Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Diseases.

Rousseau G Mar Drugs. 2021; 19(2).

PMID: 33498729 PMC: 7931107. DOI: 10.3390/md19020054.